Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Austria / NCT05450185
Recruiting Observational

Filter Lifespan in Continuous Renal Replacement Therapy

NCT05450185 · tracked via the Priya Life Science Austria tracker
Sponsor
University Hospital Muenster
Phase
Observational
Started
2023-03-02
Last updated
2024-12-12

Condition(s) studied

Critically IllContinuous Renal Replacement TherapyInfections

Investigational drug(s) / intervention(s)

Critically ill patients with continuous renal replacement therapy

Critically ill patients with continuous renal replacement therapy: Due to the observational design of the study, no study-specific interventions are performed. The treatment of the patients is completely guided by the responsible ICU physicians.

Study summary

The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with dialysis-dependent AKI * Continuous renal replacement therapy (CRRT) * Written informed consent Exclusion Criteria: * Chronic kidney disease with estimated glomerular filtration rate (eGFR)\<30ml/min/1.73m2 * Chronic dialysis dependency * Kidney transplant * (Glomerulo-)nephritis, interstitial nephritis, vasculitis * Patients on immunosuppression * Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis) * Persons with any kind of dependency on the investigator or employed by the sponsor or investigator

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Univ.-Klinik Innsbruck Innsbruck Austria Recruiting
Universidade de São Paulo São Paulo Brazil Recruiting
Universitätsklinikum Erlangen-Nürnberg, Abteilung für Nephrologie und Hypertensiologie Erlangen Germany Recruiting
Kliniken Maria Hilf, Klinik für Anästhesiologie und Operative Intensivmedizin Mönchengladbach Germany Recruiting
University Hospital Muenster Münster Germany Recruiting

More University Hospital Muenster trials in Austria

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Active, not recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05450185 on ClinicalTrials.gov ↗ ← All trials in Austria